Linaclotide是最低限度的可吸收的鸟苷酸环化酶C受体的肽激动剂。Anthony J等选择1 276例长期便秘患者,进行随机、多通道、双盲、平行对照二重剂量实验(303和01实验)。患者接受安慰剂或linaclotide治疗,剂量为145或290μg,1次/d,共12周。主要效力终点是每周出现3次及3次以上的完全自发的肠道运动(CSBMs)或至少有9周CSBMs Linaclotide is a minimally accepted peptide agonist of the guanylate cyclase C receptor. Anthony J et al selected 1 276 patients with chronic constipation for randomized, multichannel, double-blind, parallel controlled double-dose experiments (303 and 01). Patients were treated with placebo or linaclotide at a dose of 145 or 290 μg once daily for 12 weeks. The primary efficacy endpoint was complete spontaneous bowel movements (CSBMs) with 3 or more episodes per week or CSBMs with at least 9 weeks